NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00442637,Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma,https://clinicaltrials.gov/study/NCT00442637,CAIRO3,UNKNOWN,"The optimal duration of systemic treatment in patients with advanced colorectal cancer is unknown.

In this study the effects of bevacizumab and low-dose continuous chemotherapy with capecitabine is investigated in patients who have responded to 6 courses of oxaliplatin, capecitabine and bevacizumab (""induction treatment"", at standard doses). This treatment is continued until progression or severe toxicity. This regimen is compared to the effects a observation without treatment after the induction treatment.

In case of disease progression, induction treatment will be reintroduced.",NO,Colorectal Cancer Metastatic,DRUG: capecitabine + bevacizumab|OTHER: observation,"Progression-free survival after re-introduction of MTD chemotherapy and bevacizumab (PFS2), study duration","Progression-free survival between observation versus maintenance therapy (PFS1), study duration|Response rate during re-introduction of MTD chemotherapy and bevacizumab, study duration|Toxicity, study duration|Quality of life, study duration|Overall survival, study duration|Translational research, study duration",,Dutch Colorectal Cancer Group,Koningin Wilhelmina Fonds|Sanofi|Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE3,635,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CAIRO3,2007-01,2013-09,2013-12,2007-03-02,,2013-12-12,"University Medical Center Nijmegen, Nijmegen, Gelderland, Netherlands",
